Notable Labs, Ltd. (NTBL)
NASDAQ: NTBL · IEX Real-Time Price · USD
0.831
+0.031 (3.86%)
At close: May 28, 2024, 4:00 PM
0.830
-0.001 (-0.10%)
After-hours: May 28, 2024, 5:17 PM EDT
Notable Labs Revenue
Notable Labs had revenue of $311.00K in the twelve months ending March 31, 2024, down -396.19% year-over-year. Revenue in the quarter ending March 31, 2024 was $1,000.00. In the year 2023, Notable Labs had annual revenue of $310.00K with 3,775.00% growth.
Revenue (ttm)
$311.00K
Revenue Growth
-396.19%
P/S Ratio
24.09
Revenue / Employee
$19,438
Employees
16
Market Cap
7.49M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 310.00K | 302.00K | 3,775.00% |
Dec 31, 2022 | 8.00K | -760.00K | -98.96% |
Dec 31, 2021 | 768.00K | -154.00K | -16.70% |
Dec 31, 2020 | 922.00K | 360.00K | 64.06% |
Dec 31, 2019 | 562.00K | -23.00K | -3.93% |
Dec 31, 2018 | 585.00K | -13.28M | -95.78% |
Dec 31, 2017 | 13.86M | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
XWELL | 31.77M |
Intelligent Bio Solutions | 3.21M |
Trevena | 3.14M |
Longeveron | 978.00K |
Nexalin Technology | 158.86K |
Vaccinex | 124.00K |
NTBL News
- 19 days ago - Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024 - GlobeNewsWire
- 6 weeks ago - Notable Labs Reports 2023 Financial Results and Provides a Business Update - GlobeNewsWire
- 7 weeks ago - Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 - GlobeNewsWire
- 7 weeks ago - Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform - GlobeNewsWire
- 3 months ago - Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform - GlobeNewsWire
- 3 months ago - Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment - GlobeNewsWire
- 5 months ago - Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome - GlobeNewsWire
- 5 months ago - Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes - PRNewsWire